← Markets

Inspire Medical Systems, Inc.

INSP · NYSE

Market closed$50.60$-0.940000 (-1.82%)After hours $50.60 · 0.00%

Key statistics

Previous close$51.54
Open$51.01
Day high$51.26
Day low$49.68
52-week high$147.03
52-week low$38.91
Market cap1.46B
Volume448.74K
Average volume1.17M
P/E ratio19.61
Forward P/E—
EPS2.58
Dividend yield0.00%

Market context

Why it moved

INSP shares declined modestly amid continued investor concern over the company's lowered full-year revenue guidance and persistent "coding and reimbursement uncertainty" surrounding its Inspire V product, which is expected to weigh on demand throughout 2026.

StockstoryInvesting.comFacebookGolocalprovHome

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Inspire Medical Systems closed modestly lower, pulling back after a strong recent run that saw shares climb roughly 13% in July amid a broader rotation into healthcare and defensive names as institutional investors shifted out of AI and semiconductor stocks. Truist raised its price target on INSP to $54 from $50 while maintaining a Hold rating, though analyst sentiment remains cautious given an estimated 8% revenue decline over the next 12 months and a demanding 54.6x forward P/E. A Zacks analysis argues investors should retain the stock as it navigates a key product transition, but Q1 results — which showed just 1.6% revenue growth and below-consensus full-year guidance — continue to weigh on the fundamental narrative.

-1.8238

July 17, 2026Inspire Medical Systems gained over 2% during the regular session, though shares slipped back in after-hours trading, as Truist Securities raised its price target to $54 from $50 while maintaining a Hold rating — a modest vote of confidence following a challenging Q1 that saw the company deliver the weakest guidance update among specialty medical device peers. The analyst action comes amid a broadly supportive healthcare backdrop, with Abbott Labs surging on a strong Q2 beat and UnitedHealth rallying on raised guidance, though concerns linger around INSP's estimated 8% revenue decline over the next 12 months and a lofty 54.6x forward P/E.

2.0594

July 16, 2026Inspire Medical Systems closed up nearly 3% amid a broader MedTech recovery, bouncing from weakness tied to its disappointing Q1 earnings report. The company had delivered the weakest Q1 performance among specialty medical device peers—posting just 1.6% revenue growth to $204.6 million and issuing full-year guidance that missed analyst estimates—sending shares down roughly 6% since reporting. Tuesday's sector-wide MedTech selloff, driven by HCA Healthcare's reduced earnings forecast and lower surgical volumes, added further pressure before today's rebound. Freedom Capital's recent initiation with a Buy rating and $62 price target offered a positive counterweight, while UBS upgraded the broader healthcare sector on improving earnings revisions and regulatory stability.

2.7467

July 15, 2026Inspire Medical Systems shares tumbled, underperforming the broader healthcare sector, as investors continued to digest the company's disappointing Q1 earnings report — flagged as the weakest performance among specialty medical device peers — which featured below-consensus full-year revenue and EPS guidance despite a modest revenue beat. The stock has now declined over 10% since that report, with today's pressure compounding broader sector headwinds as key healthcare names like Abbott, Stryker, and Intuitive Surgical also sold off sharply amid concerns over decelerating hospital spending and a challenging reimbursement environment.

-4.303

July 14, 2026Inspire Medical Systems edged lower amid a broader risk-off session driven by renewed U.S.-Iran military exchanges that sent oil prices surging and weighed on equities, while the healthcare sector also faces headwinds heading into Q2 earnings season. Investor sentiment toward Inspire remains cautious against a backdrop of an ongoing securities class action lawsuit and a continued law firm investigation into whether company officers breached fiduciary duties following the botched 2025 Inspire V device launch — which led to a dramatic earnings guidance cut of over 80%. Despite these overhangs, the stock has posted notable gains in July, with one source noting a 13%+ advance month-to-date, and Oppenheimer reiterated a Market Perform rating in mid-June.

-0.7728

July 11, 2026Inspire Medical Systems edged modestly higher, closing up roughly 0.5%, as investors continue to digest a confluence of headwinds weighing on sentiment. Recent voluntary Class II device recalls have put the company's valuation under fresh scrutiny, while a pending securities class action alleges executives misled investors about the Inspire V next-generation device rollout—citing overstated demand and unresolved launch readiness issues including Medicare billing gaps. Analysts project an 8% revenue decline over the next 12 months, a sharp reversal from its prior 46.8% annualized growth, and the stock has shed roughly 50% over the past six months. Despite the modest bounce, the stock dipped in after-hours trading alongside a broader healthcare sector that closed lower.

0.4658

July 10, 2026Inspire Medical Systems advanced roughly 4.5%, outperforming the broader healthcare sector (XLV was essentially flat on the day) as investors positioned ahead of the company's Q2 2026 earnings call scheduled for August 3. The rally comes despite a challenging backdrop for the stock: shares have shed nearly 50% over the past six months following a troubled rollout of its next-generation Inspire V sleep apnea device, with a pending securities class action alleging executives overstated demand and readiness for the launch. Analyst sentiment remains cautious, with sell-side forecasts calling for an 8% revenue decline over the next 12 months — a sharp reversal from its prior 46.8% annualized growth — while geopolitical volatility from renewed U.S.-Iran strikes weighed on broader markets.

4.503

July 8, 2026Inspire Medical Systems closed down 1.56% amid a broad market risk-off session driven by escalating U.S.-Iran tensions — which sent oil prices surging over 5% after Trump declared the interim peace deal 'over' — and semiconductor-led tech weakness following disappointing Samsung earnings. With no company-specific negative catalysts, the pullback appears macro-driven; investors are instead focused on the upcoming Q2 2026 earnings report scheduled for August 3, after Inspire corrected the date in a July 6 announcement. Healthcare (XLV) has been a relative outperformer recently, posting sector-leading gains of 6.6% in June, though today's risk-off move weighed broadly across equities.

-1.5575

Moomoo · July 16, 2026Truist Adjusts Price Target on Inspire Medical Systems to $54 From $50, Maintains Hold RatingStock Titan · July 6, 2026Inspire Medical sets Aug. 3 earnings call after Q2 resultsMoomoo · July 4, 2026Wells Fargo Maintains Inspire Medical Systems(INSP.US) With Hold Rating, Maintains Target Price $56Simply Wall Street · June 29, 2026Why Inspire Medical Systems (INSP) Is Up 10.6% After Russell Index Reclassification To Small CapStockStory · May 5, 2026Inspire Medical Systems (INSP) Stock Trades Down, Here Is WhySimply Wall Street · March 26, 2026Inspire Medical Systems Governance Vote Arrives As Shares Trade Below TargetsPR Newswire · December 17, 2025Inspire Medical (INSP) Crashes Over 32%, "Inspire V" Launch Failure, Hagens Berman Urges Investors with Losses to Contact Firm by Jan. 5PR Newswire · December 1, 2025INSP INVESTOR ALERT: Inspire Medical (INSP) Sued Over Claims It Misled Investors on Next-Generation Device Launch -- Hagens Berman
Mt Newswire · July 16, 2026Truist Adjusts Price Target on Inspire Medical Systems to $54 From $50, Maintains Hold Rating
Benzinga · July 1, 2026Freedom Capital Markets Initiates Coverage On Inspire Medical Systems with Buy Rating, Announces Price Target of $62
Mt Newswire · June 23, 2026Evercore ISI Downgrades Inspire Medical Systems to In Line From Outperform, Adjusts PT to $40 From $55
Mt Newswire · May 22, 2026Inspire Medical Systems Faces Coding Overhang, Estimate Risks, BofA Says
Mt Newswire · May 22, 2026BofA Securities Downgrades Inspire Medical Systems to Underperform From Neutral, Price Target is $39
Benzinga · May 7, 2026Oppenheimer Maintains Perform on Inspire Medical Systemsto Perform
Benzinga · May 5, 2026JP Morgan Maintains Neutral on Inspire Medical Systems, Lowers Price Target to $54
Mt Newswire · May 5, 2026Inspire Medical Systems Faces Limited Visibility, RBC Says

Peers

S&P 500SPX · $7,457.78-1.01%ResMed Inc.RMD · $198.99-1.86%Koninklijke Philips N.V.PHG · $26.95-1.25%Medtronic plcMDT · $83.20-0.43%LivaNova PLCLIVN · $80.70-1.33%Nyxoah S.A.NYXH · $1.57-3.09%Integer Holdings CorporationITGR · $95.42-4.22%Merit Medical Systems, Inc.MMSI · $73.99-2.06%Bausch + Lomb CorporationBLCO · $16.26-3.27%Envista Holdings CorpNVST · $26.74-0.93%Penumbra, Inc.PEN · $318.32-0.40%